Carol A. Nacy
Direktor/Vorstandsmitglied bei NUGENEREX IMMUNO-ONCOLOGY, INC.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Anthony S. Crisci | M | 54 | - | |
| Thomas Leonard | M | 50 | - | |
| Leo Einck | M | - |
Sequella, Inc.
 Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD.
CASI Pharmaceuticals, Inc. /Old/
 CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | 27 Jahre |
| Joseph Moscato | M | 61 | 7 Jahre | |
| Craig Eagle | M | 57 | - | |
| Richard Purcell | M | 63 | 7 Jahre | |
| Marvin Hausman | M | 82 | - | |
| Lawrence Miller | M | - |
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | - |
| William K. Hoskins | M | 89 |
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | - |
| Eric von Hofe | M | 66 | - | |
| Brian T. McGee | M | 63 | - | |
| Paul Schulze Lefert | M | - |
American Academy of Microbiology
| - |
| Yi Yao | M | 65 |
American Academy of Microbiology
| - |
| Paige MacDonald | F | - |
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | - |
| Gail H. Cassell | M | 77 |
American Academy of Microbiology
| - |
| Herbert Virgin | M | 68 |
American Academy of Microbiology
| - |
| John H. Friedman | M | 71 |
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | - |
| Charles J. Czuprynski | M | - |
American Academy of Microbiology
| - |
| Michael Goodfellow | M | - |
American Academy of Microbiology
| - |
| William Reznikoff | M | - |
American Academy of Microbiology
| - |
| Jason Terrell | M | 43 | - | |
| Allan Jacobson | M | 78 |
American Academy of Microbiology
| - |
| Irving L. Weissman | M | 84 |
American Academy of Microbiology
| 27 Jahre |
| Lucy Shapiro | M | 83 |
American Academy of Microbiology
| - |
| Ronald I. Meltzer | M | - |
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | - |
| Robert L. Coffman | M | 77 |
American Academy of Microbiology
| - |
| Jay Winship | M | - |
American Academy of Microbiology
| - |
| Mark Corrao | M | 67 | - | |
| Bradley N. Rotter | M | 68 |
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Donald S. Brooks | M | 88 |
CASI Pharmaceuticals, Inc. /Old/
CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | 16 Jahre |
| Mark Corbet MacRae Randall | M | 61 |
CASI Pharmaceuticals, Inc. /Old/
CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | 17 Jahre |
| Wendell M. Starke | M | - |
CASI Pharmaceuticals, Inc. /Old/
CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | - |
| David Smith | M | 64 |
Anergen, Inc.
| 2 Jahre |
| John Varian | M | 64 |
Anergen, Inc.
| 6 Jahre |
| Alan Klein | M | - |
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | - |
| Marina Protopopova | M | - |
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 36 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Carol A. Nacy
- Persönliches Netzwerk
